S 
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 688505.SS · CNY
Health Care · Shanghai · 🇨🇳 China
7.03
-0.71%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥685.8m
FY2016FY2025
Net income
−CN¥157.4m
FY2016FY2025
Free cash flow
CN¥109.0m
FY2016FY2025
Shareholders' equity
CN¥2.12bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥685.8m | CN¥709.4m | CN¥850.7m | CN¥1.03bn | CN¥1.14bn | CN¥833.8m | CN¥1.03bn | CN¥741.8m | CN¥497.7m | CN¥621.9m |
| Gross profit | CN¥685.8m | CN¥645.9m | CN¥776.7m | CN¥944.9m | CN¥1.06bn | CN¥767.7m | CN¥952.1m | CN¥670.4m | CN¥442.9m | CN¥575.4m |
| Research and development | CN¥358.0m | CN¥325.8m | CN¥243.8m | CN¥226.9m | CN¥224.4m | CN¥139.3m | CN¥127.8m | CN¥119.2m | CN¥118.3m | CN¥95.8m |
| Operating income | −CN¥155.4m | CN¥2.4m | CN¥97.1m | CN¥133.3m | CN¥217.4m | CN¥173.0m | CN¥247.5m | CN¥93.0m | CN¥76.0m | CN¥155.1m |
| Net income | −CN¥157.4m | CN¥39.7m | CN¥108.6m | CN¥138.0m | CN¥213.3m | CN¥164.7m | CN¥227.4m | CN¥112.1m | CN¥75.3m | CN¥138.7m |
| Diluted earnings per share | -0.09 | 0.04 | 0.10 | 0.10 | 0.23 | 0.15 | 0.26 | 0.12 | 0.08 | 0.15 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥2.39bn | CN¥2.59bn | CN¥2.88bn | CN¥2.98bn | CN¥2.78bn | CN¥2.50bn | CN¥1.56bn | CN¥1.46bn | CN¥1.15bn | CN¥1.12bn |
| Cash and short-term investments | — | CN¥1.06bn | CN¥1.20bn | CN¥1.32bn | CN¥1.21bn | CN¥1.40bn | CN¥576.8m | CN¥588.2m | CN¥468.1m | CN¥511.3m |
| Total liabilities | CN¥273.9m | CN¥281.2m | CN¥518.1m | CN¥723.0m | CN¥591.6m | CN¥492.2m | CN¥631.7m | CN¥466.1m | CN¥252.7m | CN¥247.7m |
| Debt | — | CN¥20.5m | CN¥17.3m | CN¥124.8m | CN¥31.3m | CN¥19.7m | CN¥155.1m | CN¥150.0m | CN¥140.0m | CN¥120.0m |
| Shareholders' equity | CN¥2.12bn | CN¥2.30bn | CN¥2.36bn | CN¥2.26bn | CN¥2.19bn | CN¥2.01bn | CN¥931.5m | CN¥982.1m | CN¥872.4m | CN¥843.6m |
| Shares outstanding | 1,808m | 904m | 1,140m | 1,363m | 944m | 1,129m | 889m | 923m | 923m | 923m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥141.4m | −CN¥14.8m | CN¥71.0m | CN¥165.3m | CN¥268.9m | CN¥113.0m | CN¥269.2m | CN¥173.9m | CN¥42.7m | CN¥140.6m |
| Capital spending | −CN¥32.4m | −CN¥42.7m | −CN¥99.0m | −CN¥87.3m | −CN¥120.1m | −CN¥42.4m | −CN¥40.4m | −CN¥37.8m | −CN¥60.9m | −CN¥46.8m |
| Free cash flow | CN¥109.0m | −CN¥57.4m | −CN¥28.0m | CN¥78.0m | CN¥148.8m | CN¥70.6m | CN¥228.8m | CN¥136.1m | −CN¥18.2m | CN¥93.8m |
| Dividends paid | −CN¥31.1m | −CN¥93.3m | −CN¥76.2m | −CN¥72.0m | −CN¥52.1m | −CN¥64.6m | −CN¥64.6m | −CN¥27.7m | −CN¥46.1m | −CN¥28.0m |
Latest quarters
By quarter end
| Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥134.7m | CN¥161.0m | CN¥210.2m | CN¥179.9m | CN¥160.6m | CN¥140.7m | CN¥260.5m | CN¥147.6m |
| Gross profit | CN¥189.8m | CN¥146.1m | CN¥186.0m | CN¥163.9m | CN¥142.2m | CN¥126.2m | CN¥240.8m | CN¥136.8m |
| Operating income | −CN¥139.4m | −CN¥32.3m | CN¥3.1m | CN¥2.7m | −CN¥81.3m | CN¥11.5m | CN¥71.0m | CN¥1.2m |
| Net income | −CN¥141.5m | −CN¥21.7m | CN¥3.1m | CN¥2.7m | −CN¥46.7m | CN¥16.0m | CN¥68.1m | CN¥2.3m |
| Diluted earnings per share | -0.08 | -0.01 | 0.00 | 0.00 | -0.05 | 0.02 | 0.08 | 0.00 |
| Cash from operations | — | CN¥43.0m | CN¥55.0m | CN¥6.0m | CN¥45.0m | −CN¥87.0m | −CN¥16.0m | CN¥43.0m |
| Capital spending | — | −CN¥3.0m | −CN¥13.0m | −CN¥6.0m | −CN¥26.0m | −CN¥7.0m | −CN¥2.0m | −CN¥10.0m |
| Free cash flow | — | CN¥40.0m | CN¥42.0m | CN¥0 | CN¥19.0m | −CN¥94.0m | −CN¥18.0m | CN¥33.0m |
| Total assets | CN¥2.39bn | CN¥2.47bn | CN¥2.54bn | CN¥2.53bn | CN¥2.59bn | CN¥2.63bn | CN¥2.85bn | CN¥2.83bn |
| Cash and short-term investments | — | CN¥1.12bn | CN¥1.11bn | CN¥1.06bn | CN¥1.06bn | CN¥1.04bn | CN¥1.22bn | CN¥1.23bn |
| Debt | — | CN¥5.3m | CN¥10.8m | CN¥5.6m | CN¥6.1m | CN¥3.0m | CN¥2.1m | CN¥4.9m |
| Shareholders' equity | CN¥2.12bn | CN¥2.26bn | CN¥2.28bn | CN¥2.31bn | CN¥2.30bn | CN¥2.35bn | CN¥2.36bn | CN¥2.36bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -12.7% | -3.8% | 1.7% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 95.5% | 93.2% | 92.9% | 92.3% |
| Operating margin | -11.0% | 2.4% | 8.9% | 13.7% |
| Net margin | -8.4% | 3.9% | 9.7% | 13.6% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Price to earnings | -95.4 | 174.4 | 96.9 | 82.5 | 62.4 | 118.6 |
| Price to sales | 21.9 | 9.8 | 12.4 | 11.0 | 11.7 | 23.4 |
Dividends and splits
Per share, in the currency the company pays
Paid for 5 years. Last went ex-dividend on 18 Jul 2025.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Paid in the year | 0.03 | 0.09 | 0.07 | 0.07 | 0.05 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.